Published in Hepatitis Weekly, June 20th, 2005
According to recent research from the People's Republic of China, "previous studies reported that the HBV DNA level in maternal serum is an important risk factor for intrauterine infection. Two antiviral drugs, lamivudine (3TC) and interferon alpha (IFN alpha), are used extensively clinically to reduce maternal HBV DNA level, however, because of a lack of evidence on the efficacy and safety of these drugs during pregnancy, they are categorized as grade C, which prevents their use during pregnancy."
"This study provides new data on the efficacy and safety of lamivudine and IFN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly